Cachet Pharmaceutical Co Ltd

Cachet Pharmaceutical Co Ltd maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.49, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.75, suggesting it can cover its short-term obligations but with limited surplus. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics for Cachet Pharmaceutical Co Ltd are modest. The company's return on equity (ROE) is 2.56%, and its return on assets (ROA) is 0.87%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. These figures suggest that the company is generating limited returns relative to its equity and asset base. The company's revenue is primarily concentrated in its domestic operations, with no significant international revenue disclosed. This geographic concentration may expose the company to regional economic and regulatory risks. Additionally, the company does not disclose segment-specific revenue, making it difficult to assess the performance of individual product lines or therapeutic areas. Cachet Pharmaceutical Co Ltd's growth trajectory appears to be modest. The company's reported revenue of 19.53 billion CNY is below the analyst estimate of 23.26 billion CNY, indicating a potential shortfall in revenue performance. The company's capital expenditures are negative, suggesting a reduction in investment in new projects or facilities, which may impact long-term growth prospects. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt raises concerns about the company's ability to meet short-term obligations without additional financing. However, the low dilution risk suggests that the company is not currently issuing a significant number of new shares, which helps preserve shareholder value. Recent financial filings and disclosures indicate that the company has not issued any new shares in the near term, and there are no immediate signs of significant dilution. The company's capital structure remains relatively stable, with no major changes in long-term debt or equity issuance reported in the latest filings.